TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
 2016 Annual Meeting - EconoTimes)
SAN DIEGO, Nov. 03, 2016 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, today announced the following presentation at the upcoming Connective Tissue Oncology Society (CTOS) 2016 Annual Meeting in Lisbon, Portugal:
| Title: | TRC105 (Endoglin Antibody) in Combination with Pazopanib in Patients with Advanced Angiosarcoma | |||||||||
| Session Title: | Poster Session 2 – Soft Tissue Sarcomas - Poster 110 | |||||||||
| Presenter: | K. Kumar Sankhala, M.D., Sarcoma Oncology Research Center, Santa Monica, CA | |||||||||
| Location: | Corinthia Hotel Lisbon, Lisbon, Portugal | |||||||||
| Date/Time: | Friday, November 11, 2016, 10:40 AM – 7:00 PM, Western Europe Time | |||||||||
About TRC105 (carotuximab)
TRC105 (carotuximab) is a novel, clinical stage antibody to endoglin, a protein overexpressed on proliferating endothelial cells that is essential for angiogenesis, the process of new blood vessel formation. TRC105 is currently being studied in multiple Phase 2 clinical trials sponsored by TRACON or the National Cancer Institute for the treatment of solid tumor types in combination with VEGF inhibitors. The ophthalmic formulation of TRC105, DE-122, is currently in a Phase 1/2 trial for patients with wet AMD. TRC205, a second generation antibody to endoglin, is undergoing preclinical testing in models of fibrosis. For more information about the clinical trials, please visit TRACON’s website at http://www.traconpharma.com/clinical_trials.php.
About TRACON
TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. The Company is also developing two programs in-licensed from Janssen Pharmaceutica N.V. – TRC253, a small molecule inhibitor of wild type androgen receptor (AR) and multiple AR mutations that confer drug resistance, which is intended for the treatment of men with prostate cancer, and TRC694, a small molecule inhibitor of NF-kB inducing kinase (NIK), which is intended for the treatment of patients with hematologic malignancies, including myeloma. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
Company Contact: Casey Logan Chief Business Officer (858) 550‐0780 ext. 236 [email protected] Investor Contact: Andrew McDonald LifeSci Advisors LLC 646-597-6987 [email protected]
